Press Releases

Date Title  
04/20/21
Lantheus Holdings to Host First Quarter 2021 Earnings Conference Call and Webcast on May 4, 2021 at 8:00 a.m. Eastern Time
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 20, 2021-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Tuesday, May 4, 2021 , to discuss its financial and operating results for the first quarter of 2021.
04/07/21
Lantheus Expands R&D Leadership Team with Key New Hires
Bela Denes , MD Joins as Vice President of Medical Affairs Iryna Teslenko , MD, MBA Joins as Vice President of Clinical Development NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 7, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of
04/01/21
Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel
Names Daniel Niedzwiecki as Senior Vice President and General Counsel NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 1, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and
03/30/21
Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 30, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical
03/22/21
Lantheus Announces Presentation Featuring AZEDRA® (iobenguane I 131) at ENDO 2021
- Statistically Significant Correlation Between Biomarker Responses and Objective Tumor Response - NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 22, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of innovative imaging diagnostics,
03/01/21
Lantheus Announces Publication of PyL™ (18F-DCFPyL) Results from Pivotal Studies
OSPREY Phase 2/3 Results Published in the Journal of Urology   CONDOR Phase 3 Results Published in Clinical Cancer Research NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 1, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of innovative
02/25/21
Lantheus Reports Fourth Quarter and Full Year 2020 Financial Results
Worldwide revenue of $94.2 million and $339.4 million for the fourth quarter and full year 2020, representing an increase of 5.4% and a decline of 2.3% over the prior year period, respectively Net loss of $3.4 million and $13.5 million for the fourth quarter and full year 2020, compared to net
02/12/21
Lantheus Holdings to Present at the 10th Annual SVB Leerink Global Healthcare Conference
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 12, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical
02/11/21
Lantheus Holdings to Host Fourth Quarter and Full Year 2020 Earnings Conference Call and Webcast on February 25, 2020 at 4:30 p.m. Eastern Time
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 11, 2021-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 4:30 p.m. ET on Thursday, February 25, 2021 , to discuss its financial and operating results for the fourth quarter and
02/04/21
Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 4, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (the “Company”), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc. , and a global leader in the development, manufacture and commercialization of innovative
01/12/21
Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 12, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc. , and a global leader in the development, manufacture and commercialization of innovative